Ellenberger, David

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal - Experimental, Translational and Clinical"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Parciak, Tina"],["dc.contributor.author","Brola, Waldemar"],["dc.contributor.author","Hillert, Jan"],["dc.contributor.author","Middleton, Rod"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Thalheim, Christoph"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Ellenberger, David"],["dc.date.accessioned","2022-06-01T09:27:37Z"],["dc.date.available","2022-06-01T09:27:37Z"],["dc.date.issued","2022"],["dc.description.abstract","Background People with Multiple Sclerosis (PwMS) suffer from an increased risk of unemployment during the course of the disease. In recent years progress has been made in increasing the time until patients have to leave the workforce permanently. Such a retirement is often associated with MS but the driving factors including disability progression, support measures at the workplace, and societal aspects are not yet fully understood. Methods We consolidated data from four European MS databases from Germany, Poland, Sweden, and the United Kingdom, which were able to provide data on working status, disability progression and quality of life in accordance with the data harmonization framework of the EUReMS (European Registry in Multiple Sclerosis) project. Results Factors strongly associated with unemployment are disability progression, low quality of life and being close to the statutory retirement age. Overall, highest employment rate (77%) and lowest effects of gender and disease duration were found in Sweden. Conclusions We found remarkable differences between the European registers and the countries studied, which may indicate inequalities at European level. Furthermore, our findings suggest that it is feasible and useful to combine data from different MS registers in Europe, albeit the data structures are heterogeneous."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1177/20552173221090653"],["dc.identifier.pmid","35496757"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108532"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2055-2173"],["dc.relation.issn","2055-2173"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0/"],["dc.title","Comparison of employment among people with Multiple Sclerosis across Europe"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Neurology and Therapy"],["dc.contributor.author","Frahm, Niklas"],["dc.contributor.author","Fneish, Firas"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Warnke, Clemens"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Parciak, Tina"],["dc.contributor.author","Krefting, Dagmar"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Rommer, Paulus S."],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Zettl, Uwe K."],["dc.date.accessioned","2022-02-01T10:32:01Z"],["dc.date.accessioned","2022-08-18T12:41:03Z"],["dc.date.available","2022-02-01T10:32:01Z"],["dc.date.available","2022-08-18T12:41:03Z"],["dc.date.issued","2022-01-12"],["dc.date.updated","2022-07-29T12:18:29Z"],["dc.description.abstract","Abstract\r\n \r\n Introductions\r\n Therapy switches in patients with multiple sclerosis (MS) receiving treatment with fingolimod occur frequently in clinical practice but are not well represented in real-world data. The aim of this study was to identify and characterize treatment switches and reveal sociodemographic/clinical changes over time in fingolimod-treated people with MS (PwMS).\r\n \r\n \r\n Methods\r\n Data on 2536 fingolimod-treated PwMS extracted from the German MS Registry during different time periods were analyzed (2010–2019).\r\n \r\n \r\n Results\r\n Overall, 28.3% of PwMS were treatment-naïve before fingolimod initiation. Interferon beta (30.7%) was the most common pre-fingolimod treatment. Ocrelizumab (19.8%) was the most frequent subsequent treatment in the 944 patients on fingolimod who switched. Between 2010 and 2019, median disease duration at fingolimod initiation decreased from 8.5 to 7.1 years (p < 0.001), and patients taking fingolimod for ≥ 1 year after treatment initiation decreased from 89.6 to 80.5% (p < 0.001). Females (p < 0.001) and young patients (p = 0.003) showed a shorter time on fingolimod. The most frequent reason for switching was disease activity (relapse/MRI) despite treatment. The annualized relapse rate increased from 0.37 in patients on fingolimod to 0.47 after treatment cessation, decreasing to 0.19 after treatment with a subsequent disease-modifying drug (DMD) was initiated.\r\n \r\n \r\n Conclusion\r\n Treatment switches from fingolimod to subsequent DMDs currently occur after shorter treatment durations than 10 years ago, possibly due to the growing treatment spectrum. Planning adequate washout periods is essential and should be done on an individualized basis."],["dc.identifier.doi","10.1007/s40120-021-00320-w"],["dc.identifier.pii","320"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/99001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112988"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.publisher","Springer Healthcare"],["dc.relation.eissn","2193-6536"],["dc.relation.issn","2193-8253"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject","Multiple sclerosis"],["dc.subject","Fingolimod"],["dc.subject","Treatment switches"],["dc.subject","Rebound"],["dc.subject","Disease-modifying drug"],["dc.title","Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1523"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","1532"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Buckow, Karoline"],["dc.contributor.author","Pugliatti, Maura"],["dc.contributor.author","Kes, Vanja Basic"],["dc.contributor.author","Battaglia, Mario A."],["dc.contributor.author","Boyko, Alexey"],["dc.contributor.author","Confavreux, Christian"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Eskic, Danica"],["dc.contributor.author","Ford, David"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Fuge, Jan"],["dc.contributor.author","Glaser, Anna"],["dc.contributor.author","Hillert, Jan"],["dc.contributor.author","Holloway, Edward"],["dc.contributor.author","Ioannidou, Eva"],["dc.contributor.author","Kappos, Ludwig"],["dc.contributor.author","Kasilingam, Elisabeth"],["dc.contributor.author","Koch-Henriksen, Nils"],["dc.contributor.author","Kuhle, Jens"],["dc.contributor.author","Lepore, Vito"],["dc.contributor.author","Middleton, Rod"],["dc.contributor.author","Myhr, Kjell-Morton"],["dc.contributor.author","Orologas, Anastasios"],["dc.contributor.author","Otero, Susana"],["dc.contributor.author","Pitschnau-Michel, Dorothea"],["dc.contributor.author","Rienhoff, Otto"],["dc.contributor.author","Sastre-Garriga, Jaume"],["dc.contributor.author","Schyns-Liharska, Tsveta"],["dc.contributor.author","Sutovic, Dragana"],["dc.contributor.author","Thalheim, Christoph"],["dc.contributor.author","Trojano, Maria"],["dc.contributor.author","Vlasov, Yan V."],["dc.contributor.author","Yaldizli, Oezguer"],["dc.date.accessioned","2018-11-07T09:34:24Z"],["dc.date.available","2018-11-07T09:34:24Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Identification of MS registries and databases that are currently in use in Europe as well as a detailed knowledge of their content and structure is important in order to facilitate comprehensive analysis and comparison of data. Methods: National MS registries or databases were identified by literature search, from the results of the MS Barometer 2011 and by asking 33 national MS societies. A standardized questionnaire was developed and sent to the registries' leaders, followed by telephone interviews with them. Results: Twenty registries were identified, with 13 completing the questionnaire and seven being interviewed by telephone. These registries differed widely for objectives, structure, collected data, and for patients and centres included. Despite this heterogeneity, common objectives of the registries were epidemiology (n=10), long-term therapy outcome (n=8), healthcare research (n=9) and support/basis for clinical trials (n=8). While physician-based outcome measures (EDSS) are used in all registries, data from patients' perspectives were only collected in six registries. Conclusions: The detailed information on a large number of national MS registries in Europe is a prerequisite to facilitating harmonized integration of existing data from MS registries and databases, as well as comprehensive analyses and comparison across European populations."],["dc.identifier.doi","10.1177/1352458514528760"],["dc.identifier.isi","000343623900016"],["dc.identifier.pmid","24777278"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12994"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32165"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Multiple sclerosis registries in Europe - results of a systematic survey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]